🔬 Featured Insight from Lonza CDMO Notes Blog As new molecular formats (NMF) continue to diversify the biologics landscape, toolbox approaches to analytical methods are key to accelerating development timelines and ensuring quality. In this article, our experts share how Lonza’s analytical development services help biotech and pharma partners navigate complex modalities — from bispecifics to fusion proteins — with the right balance of speed, robustness and regulatory readiness. 👤 About the author - Jennifer Newman Jennifer Newman, Principal Scientist, Analytical Development at Lonza, brings nearly two decades of experience across biologics R&D and manufacturing. She is supporting analytical strategies for mAbs, Fc bispecific and complex programs. 📖 Read the article: https://lnkd.in/esbEy2NC #Biologics #CDMO #AnalyticalDevelopment #Lonza #IntegratedBiologics #NextGenTherapeutics #CDMONotesBlog
Platform-aligned analytics offer needed adaptability across diverse biologics pipelines by designing control strategies that travel with the modality. Lonza’s modular toolbox approach enables biotechs to respond to molecular complexity with speed and confidence by balancing development velocity with regulatory precision.